Reuters logo
BRIEF-Corvus Pharmaceuticals expands CPI-444 clinical collaboration with Genentech
2017年5月2日 / 下午12点38分 / 7 个月前

BRIEF-Corvus Pharmaceuticals expands CPI-444 clinical collaboration with Genentech

May 2 (Reuters) - Corvus Pharmaceuticals Inc:

* Corvus Pharmaceuticals expands cpi-444 clinical collaboration with Genentech

* Corvus Pharmaceuticals - Genentech will manage study operations for phase 1B/2 trial, which is expected to begin enrolling patients in second half of 2017

* Corvus Pharmaceuticals Inc - financial terms were not disclosed

* Corvus Pharmaceuticals Inc - Corvus will retain global development and commercialization rights to CPI-444

* Corvus Pharmaceuticals Inc- expanded its clinical collaboration with Genentech, a member of Roche Group

* Corvus Pharmaceuticals Inc- anticipated that randomized, controlled study will enroll up to 65 patients in treatment arm Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below